120 related articles for article (PubMed ID: 24737880)
21. HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy.
Goujard C; Girault I; Rouzioux C; Lécuroux C; Deveau C; Chaix ML; Jacomet C; Talamali A; Delfraissy JF; Venet A; Meyer L; Sinet M;
Antivir Ther; 2012; 17(6):1001-9. PubMed ID: 22865544
[TBL] [Abstract][Full Text] [Related]
22. Short communication: Effectiveness at 48 weeks of switching from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV type 1-infected patients in a Brazilian cohort.
Westin MR; Biscione F; Ribeiro KM; Greco DB; Tupinambás U
AIDS Res Hum Retroviruses; 2014 Feb; 30(2):113-7. PubMed ID: 23875625
[TBL] [Abstract][Full Text] [Related]
23. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S;
Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319
[TBL] [Abstract][Full Text] [Related]
24. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
Li H; Zheng YH; Shen Z; Liu M; Liu C; He Y; Chen J; Ou QY; Huang ZL
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(42):2973-6. PubMed ID: 18261327
[TBL] [Abstract][Full Text] [Related]
25. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
[TBL] [Abstract][Full Text] [Related]
26. Extended antiretroviral treatment interruption in HIV-infected patients with long-term suppression of plasma HIV RNA.
Achenbach CJ; Till M; Palella FJ; Knoll MD; Terp SM; Kalnins AU; Murphy RL
HIV Med; 2005 Jan; 6(1):7-12. PubMed ID: 15670246
[TBL] [Abstract][Full Text] [Related]
27. Neurodevelopmental outcomes in children with HIV infection under 3 years of age.
Foster CJ; Biggs RL; Melvin D; Walters MD; Tudor-Williams G; Lyall EG
Dev Med Child Neurol; 2006 Aug; 48(8):677-82. PubMed ID: 16836781
[TBL] [Abstract][Full Text] [Related]
28. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
[TBL] [Abstract][Full Text] [Related]
29. HIV-1 DNA proviral load in treated and untreated HIV-1 seropositive patients.
Re MC; Vitone F; Biagetti C; Schiavone P; Alessandrini F; Bon I; de Crignis E; Gibellini D
Clin Microbiol Infect; 2010 Jun; 16(6):640-6. PubMed ID: 19732081
[TBL] [Abstract][Full Text] [Related]
30. Predictors of sustained response to therapy resumption after treatment interruption in HIV-infected patients failing antiretroviral therapy.
Gianotti N; Soria A; Galli L; Castagna A; Cernuschi M; Hasson H; Lazzarin A
J Med Virol; 2004 Feb; 72(2):181-6. PubMed ID: 14695657
[TBL] [Abstract][Full Text] [Related]
31. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy.
Furtado MR; Callaway DS; Phair JP; Kunstman KJ; Stanton JL; Macken CA; Perelson AS; Wolinsky SM
N Engl J Med; 1999 May; 340(21):1614-22. PubMed ID: 10341273
[TBL] [Abstract][Full Text] [Related]
32. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
[TBL] [Abstract][Full Text] [Related]
33. Immunological and virological impact of highly active antiretroviral therapy initiated during acute HIV-1 infection.
Streeck H; Jessen H; Alter G; Teigen N; Waring MT; Jessen A; Stahmer I; van Lunzen J; Lichterfeld M; Gao X; Allen TM; Carrington M; Walker BD; Rockstroh JK; Altfeld M
J Infect Dis; 2006 Sep; 194(6):734-9. PubMed ID: 16941338
[TBL] [Abstract][Full Text] [Related]
34. CD4 lymphocyte count as a predictor of the duration of highly active antiretroviral therapy-induced suppression of human immunodeficiency virus load.
Miller V; Staszewski S; Sabin C; Carlebach A; Rottmann C; Weidmann E; Rabenau H; Hill A; Lepri AC; Phillips AN
J Infect Dis; 1999 Aug; 180(2):530-3. PubMed ID: 10395876
[TBL] [Abstract][Full Text] [Related]
35. Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.
Sherman KE; Shire NJ; Cernohous P; Rouster SD; Omachi JH; Brun S; Da Silva B
Clin Infect Dis; 2005 Oct; 41(8):1186-95. PubMed ID: 16163639
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
[TBL] [Abstract][Full Text] [Related]
37. Severe Thrombocytopenia and Acute Cytomegalovirus Colitis during Primary Human Immunodeficiency Virus Infection.
Furuhata M; Yanagisawa N; Nishiki S; Sasaki S; Suganuma A; Imamura A; Ajisawa A
Intern Med; 2016; 55(24):3671-3674. PubMed ID: 27980271
[TBL] [Abstract][Full Text] [Related]
38. Bariatric surgery: An HIV-positive patient's successful journey.
Eddy F; Elvin S; Sanmani L
Int J STD AIDS; 2016 Jan; 27(1):70-1. PubMed ID: 25663245
[TBL] [Abstract][Full Text] [Related]
39. Surrogate markers now provide physicians with the best means to manage antiretroviral therapy: the case for.
Moyle GJ; Gazzard BG; Peto T
Genitourin Med; 1997 Jun; 73(3):216-8. PubMed ID: 9306905
[No Abstract] [Full Text] [Related]
40. Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy.
Greub G; Cozzi-Lepri A; Ledergerber B; Staszewski S; Perrin L; Miller V; Francioli P; Furrer H; Battegay M; Vernazza P; Bernasconi E; Günthard HF; Hirschel B; Phillips AN; Telenti A;
AIDS; 2002 Sep; 16(14):1967-9. PubMed ID: 12351960
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
